Category Specific RSS

emyria

Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial

Biotechnology company Emyria (ASX: EMD), which develops treatments for mental health and neurological conditions, has newly inaugurated its treatment facility…

1 year ago

TGA gives green light to Emyria’s psychiatrists for MDMA therapy for PTSD

Mental health treatment provider Emyria (ASX: EMD) has announced that its psychiatry specialist has been granted "Authorised Prescriber" status by…

2 years ago

Emyria recruits first patient for its meth-assisted therapy to treat PTSD

As news of billionaire (and controversial) business magnate Elon Musk taking “microdoses of ketamine (a dissociative drug)” to manage depression…

2 years ago

Does IP ownership of MDMA compounds reduce its potential for healthcare benefits?

If you read my articles often, you would know that I can become quite laudatory when discussing small cap companies…

3 years ago

MDMA usage at University is through the roof as Emyria takes aim at mental health

Harbouring more MDMA than music festival goers, the University of Western Australia (UWA) is leading the way in research around…

4 years ago

Emyria to register cannabinoid-based medicine targeting anxiety and depression

Pharmaceuticals company Emyria (ASX: EMD) is set to commence the regulatory process of registering their cannabinoid-based medicine EMD-003 as a…

5 years ago